Centene's Chart Presents a Confusing Picture

CNC has been a hard stock to trade and to analyze

Speculative Mind Medicine Could Double or Triple From Here

My recommendation is not for the shy, timid, or new trader.

CRISPR Therapeutics Is Editing Out Its Correction

Investors can now look to buy shares of this biotech firm.

PerkinElmer Should Continue Its Rally to Record Highs in the Months Ahead

Traders should approach PKI from the long side at current levels.

AstraZeneca Is Moving the Needle

This drugmaker is making a historic upside breakout. Let's check the charts.

Biogen's Japanese Partner on Alzheimer's Drug Set for Gains

Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.

Moderna's Charts Are Bullish and Pointed Higher

Here's the area where I would like to go long MRNA.

Is It Too Late to Buy Progyny?

A Real Money subscriber asks. We answer.

As America Grows Older, So Does the Appeal of This Dividend REIT

Omega Healthcare offers a 7% yield and promise of growth.

An Updated Technical Strategy for HCA Healthcare

Let's review the charts and indicators.